First port of call for research:
Introduction to Dr Daniel Tillett (Chief Scientific Officer) ... and responding to questions on hotcopper
- New strategy - see AGM presentation (latest presentation) and the strategy announcement
- Literature review on company website
- Combo Poster (this was presented at a French Leukemia Conference)
- His opening post:
- Now that I am a director of RAC it gives me the chance to introduce myself (Daniel Tillett) to all of you. I have established a company rep account here on HC to enable me to answer the questions about RAC and bisantrene that you have. I can’t discuss market sensitive information, but I have noticed reading through the threads here that there are many questions that I can answer.
One of my aims is to improve communication with the shareholders and keep everyone updated on what is going on as best I can. I know it is not always easy with biotech, but I do think we can always improve.
- September 2019 - Dr Daniel Tillett joins Race Board
- August 2019 - Prominent Biotech investor leads investment in RACE
The following threads explore various aspects of the RACE Oncology strategy:
Other:
- Theoretical Revenue Potential of RACE Oncology 5-path Strategy
- Probability Scoring for Investment in Pre-approval Biotechs [important]
- The Priority Review Voucher
First port of call for research: New strategy - see AGM...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
-0.050(3.85%) |
Mkt cap ! $216.0M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.30 | $1.25 | $77.53K | 61.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 6504 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 599 | 1 |
View Market Depth
| Last trade - 15.55pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.25 |
Change
-0.050 ( 1.91 %) |
||||
| Open | High | Low | Volume | ||
| $1.27 | $1.29 | $1.25 | 5875 | ||
| Last updated 15.55pm 30/04/2024 ? | |||||
| RAC (ASX) Chart |